Insmed Inc (STU:IM8N)
€ 67 0.5 (0.75%) Market Cap: 11.95 Bil Enterprise Value: 11.50 Bil PE Ratio: 0 PB Ratio: 25.75 GF Score: 63/100

Insmed Inc at Nasdaq Investor Conference Transcript

Dec 07, 2022 / 01:30PM GMT
Release Date Price: €18.1 (-4.23%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Okay. Great. Well, thanks for staying for the next session. I'm pleased to have Will Lewis, the CEO of Insmed with us here. Just a reminder, before we get started, I have to just make a disclosure statement. Remember that personal holdings disclosures can be found on the Morgan Stanley website at morganstanley.com/researchdisclosures. And with that, I'm going to turn it over to Will to make a couple of opening comments on the pillars of the company, and then we'll jump into Q&A.

William H. Lewis
Insmed Incorporated - President, CEO & Chairman

Thank you very much. I appreciate the opportunity to be here. Insmed is in an interesting place because we've just come off our strongest quarter in our history, and I've been at the company for 10 years now, and we think of ourselves as being made up of 4 pillars. One is ARIKAYCE, our approved product for the treatment of refractory MAC lung disease. It's approved in the U.S., Europe and Japan. We built out our own commercial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot